THE US Food and Drug
Administration has given final
approval to Mylan Pharmaceuticals
application for clopidogrel tablets
USP 75mg and 300mg.
It’s the generic version of Sanofi-
Aventis’ Plavix, indicated for acute
coronary sydrome and for patients
with a recent history of myocardial
infarction, stroke or established
peripheral arterial disease.
Mylan will have 180 days of
marketing exclusivity for the 300mg
strength which will be supplied in
unit dose packs of 30.The above article was sent to subscribers in Pharmacy Daily's issue from 18 May 12 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 18 May 12
THE stark health inequalities between Australians living in regional and metro areas have been highlighted in a new report from The Royal Flying Doctor Service (RFDS).
AN “AI explosion” is sweeping Australia’s healthcare sector, signalling the arrival of an “extraordinary era of medicine”, according to a new report from CSIRO.
THE Australian and New Zealand College of Advanced Pharmacy (ANZCAP) has celebrated the 1,000th pharmacist to complete its pharmacy recognition program (PD 24 Nov 2023).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.